Precision Biosciences (DTIL) Non-Current Assets (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Non-Current Assets of $35.2 million for Q1 2026, down 16.81% year-over-year from $42.3 million in Q1 2025, and down 1.34% quarter-over-quarter from $35.7 million in Q4 2025.
Precision Biosciences (DTIL) Non-Current Assets (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Non-Current Assets for 9 consecutive years, with $35.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 16.81% year-over-year to $35.2 million; the TTM figure through Mar 2026 stood at $151.3 million (up 2.12% YoY), while the FY2025 annual figure was $35.7 million, down 13.82% from the prior year.
- Non-Current Assets eased to $35.2 million in Q1 2026 per DTIL's latest filing, from $35.7 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $49.5 million in Q2 2022 and bottomed at $18.5 million in Q3 2023.
- Historically, Non-Current Assets has averaged $36.3 million across 5 years, with a median of $38.7 million in 2025.
- Annual changes were most pronounced in 2023 — Non-Current Assets slumped 60.12% — and 2024, when it surged 131.1%.
- Precision Biosciences' Non-Current Assets stood at $39.1 million in 2022, then slumped by 40.04% to $23.4 million in 2023, then soared by 76.75% to $41.4 million in 2024, then dropped by 13.82% to $35.7 million in 2025, then decreased by 1.34% to $35.2 million in 2026.
- Business Quant data shows DTIL's Non-Current Assets at $35.2 million in Q1 2026, $35.7 million in Q4 2025, and $41.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | 18.06 Bn |
| 10 | Precision Biosciences | 224.82 Mn | 137.27 Mn | - | 34.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.37 Mn |
| Mar 31, 2026 | 35.20 Mn |
| Dec 31, 2025 | 35.68 Mn |
| Sep 30, 2025 | 41.81 Mn |
| Jun 30, 2025 | 38.67 Mn |
| Mar 31, 2025 | 42.31 Mn |
| Dec 31, 2024 | 41.40 Mn |
| Sep 30, 2024 | 42.74 Mn |
| Jun 30, 2024 | 21.77 Mn |
| Mar 31, 2024 | 23.91 Mn |
| Dec 31, 2023 | 23.42 Mn |
| Sep 30, 2023 | 18.49 Mn |
| Jun 30, 2023 | 33.83 Mn |
| Mar 31, 2023 | 35.49 Mn |
| Dec 31, 2022 | 39.06 Mn |
| Sep 30, 2022 | 46.37 Mn |
| Jun 30, 2022 | 49.47 Mn |
| Mar 31, 2022 | 47.30 Mn |
| Dec 31, 2021 | 49.74 Mn |
| Sep 30, 2021 | 44.15 Mn |